Bios Partners
Time 2022-09-20 17:28:19Web Name: Bios Partners
WebSite: http://www.biospartners.com
ID:322436
Keywords:
Bios,PartnersDescription:
COVID-19 reports:
Brief DashboardThe Big Idea
Disrupting
The Geographic Favoritism
Great science is evenly distributed throughout the country. However, venture capital tends to be concentrated on the coasts—especially in Silicon Valley and the Northeastern US. We seek to disrupt this “geographic favoritism”, investing in opportunities with equally compelling science across the Central US that are often overlooked and undervalued. Learn More Portfolio
Learn More Medical Devices 410 Medical is a commercial-stage medical device company dedicated to developing innovative products that enable frontline medical providers to improve care for critically ill patients. Medical Devices Abilitech Medical is a medical device company bringing innovative solutions to market that allow people living with upper-limb neuromuscular conditions to function independently. Advanced small molecules Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. Microbiome-based products Azitra is a clinical-stage medical dermatology company that combines the power of the microbiome with cutting-edge genetic engineering to treat skin disease. Advanced small molecules Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company focused on synaptic health and restoration in neurodegenerative disorders through a pipeline of disease modifying small molecule drug candidates. Advanced small molecules Encore Vision is a clinical-stage subsidiary of Novartis that is developing novel small molecule therapies for the topical treatment of presbyopia, a condition of worsening vision due to aging. Medical Devices i-Lumen Scientific, Inc. is a medical company developing a next-generation, non-invasive, transpalpebral microcurrent electrical stimulation device to treat patients with visual acuity loss due to retinal degeneration. Engineered cell therapy Immusoft Corporation’s (immusoft.com) mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs the cells to produce gene-encoded medicines (biologics) for rare genetic diseases. Engineered cell therapy IN8bio (NASDAQ: INAB) is a clinical-stage immune-oncology company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. Digital medicines/AI Lantern Pharma (NASDAQ: LTRN) is a clinical stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. Lantern leverages advances in machine learning, genomics and artificial intelligence to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Recombinant proteins/antibodies Lung Therapeutics is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. Advanced small molecules ONL Therapeutics is a clinical staged company with a novel approach to preserving sight and halting vision loss associated with a range of retinal disease. The company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the Fas pathway. Opus Genetics is a preclinical company developing ocular AAV gene therapies to address a large pipeline of rare genetic blinding conditions that have no current treatment options. SIRPant Immunotherapeutics is a preclinical immuno-oncology company developing an innovative, enhanced macrophage cell therapy platform for the treatment of a broad range of solid tumors by facilitating the activation of the patient's own immune system. Recombinant proteins/antibodies Stream Biomedical is a preclinical biotechnology company focused on leveraging its engineered perlecan domain V to develop first-in-class treatments for serious neurogenerative disorders such as stroke. Engineered cell therapy Taysha Gene Therapies (NASDAQ: TSHA) is a clinical staged company focused on the treatment of monogenic CNS disease. Taysha is advancing an extensive AAV gene therapy pipeline, with lead candidates in GM2 gangliosidosis, Rett syndrome, and CLN1. Recombinant proteins/antibodies Trefoil Therapeutics is a preclinical biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders.Our Expertise
Meet our Team
Bios Partners Has A Combined 80 Years Of Experience
In Hedge Funds, Private Equity, Clinical Drug Development And Public Pharma/Biotech Analysis Learn MoreLatest News
MN Cup Winner Abilitech Medical Secures $7.4M, Eyes FDA Approval
Read More<<< Thank you for your visit >>>
Websites to related : Bloominess – Quality, sust
Skip to contentMenu HomeAbout BloominessTrends & Innovation DurabilityContactEnglishNederlandsFrançaisDeutsch1We make flowers and plants excitin
Accueil - IMS PARTNERSServices informatiques complets, dans le 67 et le 68 03 54 84 18 96Demande d'assistanceEspace client AccueilSolutions informatiquesInfrastructureT
Pearl Cohen | Your Global PartneClick to open contact form. Your Global Partners in the Business of Innovation
StoneX Partners - City Index | FMenu Login HomeLoginEarn up to $1,000 CPAPartner with StoneX and earn up to $1,000 CPA* for each qualified client you introduce to us. Choose f
Genesis PartnersGenesis Partners Genesis Partners Genesis Partners team Portfolio Media Focus Partners login →FacebookLinkedinThe junction
Klub Biosfera – program lojalnoPlease enable JavaScript to continue using this application.
Home - H2 Equity partnersSkip to contentHomeInvestmentScopeProcessPortfolio supportTrack recordESGPortfolioTeamNewsRecentArchiveContactMenuHomeInvestmentScopeProcessPortfolio
Quantum Capital Partners - HomeHome Contact Us: (813) 280-1720 Investment Process Ph
Synergy Partners | Chicago, ILEmployee Log-In menuConstructionDevelopmentWho We AreNewsContact UsA collaboration of forces to produce superior results in innovative shared offices
Home | Greater Richmond Partnersads
Hot Websites